Oxybutynin
| Evidence Level: L5 | Predicted Indications: 3 |
Table of Contents
Oxybutynin: From Overactive Bladder to Restless Legs Syndrome
One-Sentence Summary
Oxybutynin is an antimuscarinic (M1/M3 receptor antagonist) commonly used to treat overactive bladder and urge urinary incontinence. The TxGNN model’s top-ranked prediction suggests possible efficacy in Restless Legs Syndrome (RLS), but this direction currently has zero clinical trials and zero publications in direct support — it rests entirely on the model’s prediction score.
Quick Overview
| Item | Content |
|---|---|
| Original Indication | Not documented in this evidence pack (Taiwan license data is empty; based on general pharmacological knowledge, oxybutynin is used for overactive bladder / urge urinary incontinence) |
| Predicted New Indication | Restless Legs Syndrome |
| TxGNN Prediction Score | 99.74% |
| Evidence Level | L5 |
| Taiwan Market Status | Not Marketed (Not marketed) |
| Number of Registrations | 0 |
| Recommended Decision | Hold |
Why is This Prediction Reasonable?
Currently, detailed mechanism of action data is not available for oxybutynin in this evidence pack (data gap, High severity). Based on general pharmacological knowledge, oxybutynin is an anticholinergic/antimuscarinic agent that blocks M1/M3 muscarinic acetylcholine receptors, relaxing detrusor smooth muscle — the established basis for its use in overactive bladder.
For the top-ranked prediction, restless legs syndrome, the mechanistic case is weak. RLS pathophysiology is primarily driven by central dopaminergic dysfunction and iron metabolism abnormalities, and standard treatments are dopamine agonists, α2δ calcium-channel ligands, or iron replacement. Oxybutynin’s anticholinergic action has no established connection to these pathways. Consistent with this, the evidence pack shows no clinical trials, no ICTRP registrations, and no PubMed literature linking oxybutynin to RLS — the prediction is model-score-only (L5), the lowest evidence tier.
By contrast, two lower-ranked predictions in this pack have somewhat more grounding: peptic ulcer disease (rank 3, L3) is supported by literature describing oxybutynin’s antispasmodic/anticholinergic effect on gastric acid secretion and GI smooth muscle — a mechanism plausible for pre-PPI-era antispasmodic use, though one case report also documents oxybutynin-induced reflux esophagitis via lower esophageal sphincter relaxation, indicating a double-edged mechanistic risk.
Clinical Trial Evidence
Currently no related clinical trials registered
Literature Evidence
Currently no related literature available
Taiwan Market Information
Oxybutynin is currently not marketed in Taiwan under this evidence pack — 0 registered licenses, no product/dosage-form data available.
Safety Considerations
Drug Interactions (205 total interactions on record; representative entries):
- Major: Potassium chloride, Potassium citrate — reduced GI motility from anticholinergic effect can prolong mucosal contact with solid potassium salts, increasing risk of GI ulceration/irritation.
- Moderate: Additive anticholinergic burden with other antimuscarinics — Atropine, Hyoscyamine, Glycopyrronium (oral and topical), Clidinium, Dicyclomine, Trospium, Mepenzolate, Methscopolamine, Propantheline.
- Moderate: Reduced GI motility affecting opioid pharmacodynamics — Morphine (including liposomal), Loperamide, Opium.
- Moderate: Metoclopramide (prokinetic antagonism), Aprepitant, Pramlintide, Eluxadoline.
Detailed key warnings and contraindications are not available in this evidence pack (data gap, Blocking severity) — please refer to the package insert once obtained.
Conclusion and Next Steps
Decision: Hold
Rationale: The top-ranked predicted indication (restless legs syndrome) has no clinical trial or literature support and no clear mechanistic rationale — evidence level L5 is insufficient to proceed. The drug is also not currently marketed in Taiwan, so there is no existing safety/labeling foundation to build on.
To proceed, the following is needed:
- Taiwan package insert / warnings and contraindications (currently a Blocking data gap)
- Confirmed mechanism of action data from DrugBank or primary literature
- If pursuing repurposing further, consider re-evaluating the peptic ulcer disease candidate (rank 3) instead, which has L3 evidence (3 publications) versus RLS’s L5
- Formal literature/trial search specifically for oxybutynin + RLS to confirm the absence of supporting evidence is not a search-coverage artifact
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.